NCT06997926

Brief Summary

Itch is defined as an unpleasant sensation that evokes the desire to scratch. Chronic itch, defined as itch persisting for more that 6 weeks, is a key symptom in many diseases severely affects the quality of life of the affected patients and represents a substantial economic burden for the society. At present, there are no effective treatments for chronic itch diseases. Moreover, chronic itch patients express differences in their genes compared with people who do not suffer from itch. With this experiment, we wish to analyse differences in genes expression in healthy volunteers who have been exposed to artificial itch from small plant needles from the plant cowhage (mucuna pruriens) and compare them to controls who have not been exposed to itch.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
20mo left

Started May 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress37%
May 2025Dec 2027

Study Start

First participant enrolled

May 15, 2025

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

May 22, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

May 31, 2025

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2026

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2027

Last Updated

June 4, 2025

Status Verified

May 1, 2025

Enrollment Period

1.6 years

First QC Date

May 22, 2025

Last Update Submit

May 30, 2025

Conditions

Outcome Measures

Primary Outcomes (8)

  • miRNA expression over time

    Plasma miRNA evaluation

    Before active/inactive cowhage

  • miRNA expression over time

    Plasma miRNA evaluation

    30 minutes post-Active/inactive cowhage

  • miRNA expression over time

    Plasma miRNA evaluation

    3 hours post-active/inactive cowhage

  • miRNA expression over time

    Plasma miRNA evaluation

    24 hours post-active/inactive cowhage

  • Protein expression over time

    Plasma protein evaluation

    Before active/inactive cowhage

  • Protein expression over time

    Plasma protein evaluation

    30 minutes post-active/inactive cowhage

  • Protein expression over time

    Plasma protein evaluation

    3 hours post-active/inactive cowhage

  • Protein expression over time

    Plasma protein evaluation

    24 hours post-active/inactive cowhage

Secondary Outcomes (2)

  • Assessment of itch: visual analog scale (VAS)

    Immediately after Active/inactive cowhage

  • Assessment of pain: visual analog scale (VAS)

    Immediately after Active/inactive cowhage

Study Arms (2)

Active cowhage

ACTIVE COMPARATOR

The participant will receive active cowhage in the forearm.

Procedure: blood sampling

Inactive cowhage

SHAM COMPARATOR

The participant will receive inactive cowhage in the forearm.

Procedure: blood sampling

Interventions

Whole blood samples (5 mL per each time point, a total of 20 mL per subject) will be collected

Active cowhageInactive cowhage

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy men and women
  • years
  • Speak and understand English

You may not qualify if:

  • Pregnancy or lactation
  • Drug addiction defined as any use of cannabis, opioids, or other addictive drugs
  • Previous or current history of neurological (e.g., neuropathy), immunological (e.g., asthma, immune deficiencies, arthritis) musculoskeletal (e.g., muscular pain in the upper extremities), cardiac disorder, or mental illnesses that may affect the results,
  • Lack of ability to cooperate
  • Current use of medications that may affect the trial such as antihistamines, antipsychotics, and pain killers, as well as systemic or topical steroids
  • Allergy to lidocaine
  • Skin diseases (e.g., atopic dermatitis, pruritus nodularis, eczema, psoriasis)
  • Moles, scars, or tattoos in the area to be treated or tested.
  • Consumption of alcohol or painkillers 24 hours before the study days and between these
  • Smoking
  • Acute or chronic pain
  • Participation in other trials within one week of study entry (four weeks in the case of pharmaceutical trials)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Aalborg University

Gistrup, 9260, Denmark

Location

MeSH Terms

Conditions

Pruritus

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Skin DiseasesSkin and Connective Tissue DiseasesSkin ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeInvestigative Techniques

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Masking Details
The participants are blinded about receiving active or inactive cowhage
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Model Details: Two groups of subjects: one group will receive active cowhage spicules (itch inducer) and the other group will receive inactivated cowhage spicules (control)
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate professor

Study Record Dates

First Submitted

May 22, 2025

First Posted

May 31, 2025

Study Start

May 15, 2025

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

December 31, 2027

Last Updated

June 4, 2025

Record last verified: 2025-05

Data Sharing

IPD Sharing
Will not share

Locations